Skip to main content
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 1998;76(2):135–141.

Priority during a meningitis epidemic: vaccination or treatment?

H Veeken 1, K Ritmeijer 1, B Hausman 1
PMCID: PMC2305636  PMID: 9648353

Abstract

From November 1995 to May 1996, a meningitis epidemic occurred in northern Nigeria. More than 75,000 cases and 8440 deaths (case fatality rate (CFR), 11%) were recorded. Médecins sans Frontières, in cooperation with the Nigerian government, carried out an assistance programme (support to case management, surveillance and mass vaccination) in three states (Bauchi, Kano, Katsina) where 75% of cases occurred. Cost analysis of this assistance in Katsina State reveals that case management and mass vaccination were efficient: US$ 35 per case treated and US$ 0.64 per vaccination. There was, however, a remarkable difference in cost-effectiveness between the two strategies. The cost per death averted by improved case treatment was estimated to be US$ 396, while the cost per death averted by vaccination was estimated to be US$ 6000. In large part this difference is attributed to the late start of vaccination: more than 6 weeks after the epidemic threshold had been passed. During meningitis epidemics in countries where surveillance systems are inadequate, such as in most of sub-Saharan Africa, curative programmes should have priority.

Full text

PDF
135

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Moore P. S. Meningococcal meningitis in sub-Saharan Africa: a model for the epidemic process. Clin Infect Dis. 1992 Feb;14(2):515–525. doi: 10.1093/clinids/14.2.515. [DOI] [PubMed] [Google Scholar]
  2. Pinner R. W., Onyango F., Perkins B. A., Mirza N. B., Ngacha D. M., Reeves M., DeWitt W., Njeru E., Agata N. N., Broome C. V. Epidemic meningococcal disease in Nairobi, Kenya, 1989. The Kenya/Centers for Disease Control (CDC) Meningitis Study Group. J Infect Dis. 1992 Aug;166(2):359–364. doi: 10.1093/infdis/166.2.359. [DOI] [PubMed] [Google Scholar]
  3. Reingold A. L., Broome C. V., Hightower A. W., Ajello G. W., Bolan G. A., Adamsbaum C., Jones E. E., Phillips C., Tiendrebeogo H., Yada A. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet. 1985 Jul 20;2(8447):114–118. doi: 10.1016/s0140-6736(85)90224-7. [DOI] [PubMed] [Google Scholar]
  4. Ritmeijer K. Artsen zonder Grenzen en de meningitisepidemie in Niger in 1995: vaccineren of behandelen? Ned Tijdschr Geneeskd. 1996 Aug 3;140(31):1613–1616. [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES